Real-World Studies
Real-World Outcomes of Mirvetuximab Soravtansine in Recurrent Ovarian Cancer
Jones et alGynecologic Oncology Reports
In a retrospective cohort study conducted across a tertiary NCI-designated cancer center and an affiliated private hospital, researchers evaluated the real-world effectiveness and safety of mirvetuximab soravtansine (MIRV), an antibody-drug conjugate targeting folate receptor alpha (FRα), among 66 patients with recurrent ovarian cancer treated between and . While pivotal clinical trials established favorable efficacy under rigorous trial eligibility criteria, real-world data have been limited regarding broader patient populations with advanced disease and heavy pretreatment.
The study population reflected typical advanced recurrent disease encountered in clinical practice: 89% had stage IIIC–IVB disease, 77% had received three or more prior lines of therapy, 52% had platinum-resistant disease, and 86% had an initial ECOG performance status (PS) of 0 or 1. FRα expression was positive in 77% of evaluated cases. Using Kaplan-Meier analysis and multivariable Cox proportional hazards modeling, investigators determined that mirvetuximab soravtansine achieved a median progression-free survival (PFS) of 5.3 months (95% CI 4.1–7.1) and a median overall survival (OS) of 16.4 months (95% CI 12.4 to NE). Notably, neither PFS nor OS showed significant divergence based on platinum sensitivity status.
Survival outcomes were heavily stratified by functional status at baseline. Patients with an ECOG PS >1 experienced a substantially shortened median OS of 6.0 months compared with 20.3 months in patients with an ECOG PS of 0–1 (P = 0.0006). Toxicity was documented in 91% of patients. These findings suggest that while mirvetuximab soravtansine confers clinically meaningful disease control regardless of platinum status in real-world settings, performance status is a critical prognostic factor, warranting careful patient selection, realistic prognostic counseling for patients with functional impairment, and vigilant toxicity management.
Key Takeaways
- Mirvetuximab soravtansine yielded a median progression-free survival of 5.3 months (95% CI 4.1–7.1) and a median overall survival of 16.4 months (95% CI 12.4 to NE) in recurrent ovarian cancer, with survival outcomes that did not differ by platinum status.
- Baseline ECOG performance status >1 was significantly associated with markedly shorter overall survival compared with performance status 0–1 (median 6.0 vs 20.3 months; P = 0.0006).
- Treatment-related toxicity occurred in 91% of patients in this real-world cohort, underscoring the necessity of proactive adverse-event monitoring.
Read the original sourceGynecologic Oncology Reports
